Tacrolimus Capsules Recalled for Wrong-Strength Tablets Co-Mingled in Bottles
Dr. Reddy's Laboratories is recalling Tacrolimus 0.5 mg capsules due to the presence of one 1 mg capsule co-mingled in affected bottles. The mismatched capsule could lead to incorrect dosing in immunosuppressed patients.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving a medication dosage mix-up. Although no illnesses have been reported, the incorrect dose of this immunosuppressant could cause serious adverse effects. The hazard represents risk-of-harm products where injury has not yet been reported.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Tacrolimus Capsules, USP, 0.5 mg, 100-count bottles (Lot # C2106445, expiration 03/2024) distributed nationwide in the United States. The recall was initiated because one Tacrolimus 1 mg capsule was found co-mingled in bottles labeled as containing 0.5 mg capsules.
Tacrolimus is an immunosuppressant medication used to prevent organ rejection after transplantation and to treat certain autoimmune conditions. The presence of a higher-strength capsule in a bottle labeled with a lower strength creates a risk that a patient could unknowingly take an incorrect dose, potentially resulting in serious adverse effects.
Patients who are currently taking Tacrolimus from the affected lot should contact their healthcare provider or pharmacist to verify whether their bottle may be affected. Patients should not discard their medication without consulting a healthcare professional first, as Tacrolimus typically requires careful management and supervised dosing changes.
The recalled product
- Product
- TACROLIMUS (TACROLIMUS)
- Brand
- TACROLIMUS
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug
- Affected units
- 4,320
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # C2106445
- Exp. 03/2024
UPCs (3)
- 0355111527015
- 0355111525011
- 0355111526018
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · TACROLIMUS
- HighPrescription Tacrolimus Capsules Recalled for Wrong-Strength Product Mix
FDA (Drugs) · 2024-01-17
- LowTacrolimus Ointment Recalled for Defective Containers That Split
FDA (Drugs) · 2022-08-10
- LowStrides Pharma Recalls Tacrolimus Capsules for Failed Moisture Limits
FDA (Drugs) · 2021-01-06
- ModerateMylan Recalls Tacrolimus Capsules Due to Potential Foreign Capsule Presence
FDA (Drugs) · 2020-04-01
- SevereSandoz Recalls Tacrolimus Capsules Due to Fluvastatin Cross-Contamination
FDA (Drugs) · 2014-01-01
Same manufacturer · Dr. Reddy's Laboratories, Inc.
See all →- ModerateVarenicline tablets recalled after an assay value fell below specification
FDA (Drugs) · 2025-12-17
- Moderate
- HighOmeprazole capsule bottle contained a foreign divalproex sodium tablet
FDA (Drugs) · 2025-07-23
- SevereLevetiracetam Injection Label Mismatch Nationwide Recall
FDA (Drugs) · 2025-04-23
- ModerateFDA Recalls JAVYGTOR Tablets Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-12-18
Same hazard · medication error
See all →- HighIV Administration Sets from Windstone Medical for Infusion Pump Systems
FDA (Devices) · 2026-04-29
- HighMedline Industries IV Administration and Extension Sets Recalled Due to Potential Leaks
FDA (Devices) · 2026-02-25
- HighBD Pyxis Medication Dispensing Systems Software Sync Error Recall
FDA (Devices) · 2025-03-26
- ModeratePrescription statin LIVALO tablets recalled due to foreign tablets in bottles
FDA (Drugs) · 2025-03-19
- HighPyxis Medication and Anesthesia Dispensing Systems Recalled for Software Vulnerabilities
FDA (Devices) · 2025-02-19